IJU Case Reports | |
Seronegative rheumatoid arthritis after combination therapy with ipilimumab and nivolumab for postoperative pancreatic and liver metastases from renal cell carcinoma | |
article | |
Yuki Nishimura1  Kazuaki Yamanaka1  Taigo Kato1  Koji Hatano1  Atsunari Kawashima1  Shinichiro Fukuhara1  Motohide Uemura1  Ryoichi Imamura1  Norio Nonomura1  | |
[1] Department of Urology, Osaka University Graduate School of Medicine | |
关键词: immune-related adverse event; ipilimumab; nivolumab; renal cell carcinoma; seronegative rheumatoid arthritis; | |
DOI : 10.1002/iju5.12560 | |
学科分类:社会科学、人文和艺术(综合) | |
来源: Wiley | |
【 摘 要 】
IntroductionSince the approval of immune checkpoint inhibitors for renal cell carcinoma treatment, therapeutic efficacy has been enhanced. However, although autoimmune-related side effects may occur, rheumatoid immune-related adverse events seldom develop. Case presentationA 78-year-old Japanese man with renal cell carcinoma developed pancreatic and liver metastases after bilateral partial nephrectomy and was treated with ipilimumab and nivolumab. After 22 months, he developed arthralgia in limbs and knee joints, accompanied by limb swelling. The diagnosis was seronegative rheumatoid arthritis. Nivolumab was discontinued, and prednisolone was initiated, quickly improving symptoms. Although nivolumab was resumed after 2 months, arthritis did not recur. ConclusionImmune checkpoint inhibitors may cause a wide variety of immune-related adverse events. When arthritis is encountered during immune checkpoint inhibitor administration, seronegative rheumatoid arthritis should be differentiated from other types of arthritis, despite being less frequent.
【 授权许可】
CC BY|CC BY-NC|CC BY-NC-ND
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202307080005081ZK.pdf | 2283KB | download |